Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab

Background Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. Methods Adult patients comple...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2017-06, Vol.62 (6), p.1590-1596
Main Authors: Allegretti, Jessica R., Barnes, Edward L., Stevens, Betsey, Storm, Margaret, Ananthakrishnan, Ashwin, Yajnik, Vijay, Korzenik, Joshua
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Biochemistry
C-Reactive Protein - metabolism
Care and treatment
Colitis, Ulcerative - blood
Colitis, Ulcerative - drug therapy
Crohn Disease - blood
Crohn Disease - drug therapy
Crohn's disease
Drug Therapy, Combination
Female
Gastroenterology
Gastrointestinal Agents - therapeutic use
Hepatology
Hospitalization
Humans
Immunologic Factors - therapeutic use
Inflammatory bowel disease
Male
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Multivariate analysis
Oncology
Original Article
Remission (Medicine)
Remission Induction
Retrospective Studies
Severity of Illness Index
Time Factors
Transplant Surgery
Ulcerative colitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. Methods Adult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey–Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment. Results Among 136 total patients (96 CD and 40 UC), 76 (56%) demonstrated clinical response or remission at week 54. In univariate analysis, for patients with CD concomitant initiation of immunomodulator therapy (2.71, 95% CI 1.11–6.57), the addition of an immunomodulator (OR 11.49, 3.16–41.75) and CRP 
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-017-4549-3